CA2498636C - Use of saccharomyces cerevisiae erg4 mutants for the expression of glucose transporters from mammals - Google Patents

Abstract

The invention relates to yeast strains in which a human GLUT4 transporter or a human GLUT1 transporter can be functionally expressed and in particular GLUT4 transport proteins which can be particularly easily functionally expressed in yeast strains.

Description

Use of Saccharomyces cerevisiae erg4 mutants for the expression of glucose transporters from mammals.

The invention relates to yeast strains in which the human Glut 4 and Glut 1 transporters can be functionally expressed.

Most heterotropic cells transport glucose via special transporter proteins into the cell interior. The various organisms have developed different mechanisms mediating the transporting of glucose, such as, in particular, proton symport systems, Na' glucose transporters, binding protein-dependent systems, phosphotransferase systems, and systems for facilitated diffusion. In the eukaryotes, a family of glucose transporters which are encoded in mammals by the GLUT genes (GLUT = glucose transporter) and Saccharomyces cerevisiae by the HXT genes (HXT = hexose transporter) mediates glucose uptake via facilitated diffusion. Said transporters belong to a larger family of sugar transporters. They are characterized by the presence of 12 transmembrane helices and by a plurality of conserved amino acid radicals.
Glucose transport plays an important part in disorders associated with a defective glucose homeostasis, such as, for example, diabetes mellitus or Fanconi-Bickel syndrome. The glucose transport in mammals has therefore been the subject of numerous studies. To date, thirteen glucose transporter-like proteins have been identified (GLUT1 to GLUT12, HMIT - H-myo-inositol transporter)). Said transporters play key parts which include the uptake of glucose into various tissues, its storage in the liver, its insulin-dependent uptake into muscle cells and adipocytes and glucose measurement by the t cells of the pancreas.
GLUT1 mediates the transport of glucose into erythrocytes and through the blood-brain barrier, but is also expressed in many other tissues, while GLUT4 is limited to insulin-dependent tissues, primarily to muscle and fatty tissue. In said insulin-dependent tissues, controlling the targeting of GLUT4 transporters through intracellular compartments or plasma membrane compartments represents an important mechanism for regulating glucose uptake. In the presence of insulin, intracellular GLUT 4 is redistributed through the plasma membrane in order to facilitate glucose uptake. GLUT1 is likewise expressed in said insulin-dependent tissues, and its distribution in the cell is likewise influenced by insulin, albeit not as strongly. In addition, the relative efficacy with which GLUTI or GLUT4 catalyze sugar transport is determined not only by the extent of the targeting of each transporter to the cell surface but also by their kinetic properties.
The fact that different glucose transporter isoforms are coexpressed and the rapid glucose metabolism have rendered studies on the role and the exact properties of each glucose transporter isoform in these insulin-dependent tissues complicated. In order to solve these problems, heterologous expression systems such as Xenopus oocytes, tissue culture cells, insect cells and yeast cells have been used.
However, it turned out that a number of difficulties appeared in connection with these systems:
too weak an activity of the heterologously expressed transporters, intrinsic glucose transporters in said systems, intracellular retention of a considerable proportion of the transporters or even production of inactive transporters.
Naturally occurring GLUT4 protein of mammals, in particular that of humans, can be expressed in a functional manner in strains of Saccharomyces cerevisiae under particular conditions.
Yeast cells are unicell eukaryotic organisms. They are therefore, for some proteins, more suitable for expression than bacterial systems, in particular with regard to carrying out screen assays for identifying pharmaceutically active substances.

The present invention relates to a purified and isolated polynucleotide comprising a DNA sequence which codes for the GLUT4V85M protein.
Said protein contains at position 85 of the amino acid chain of the human protein an amino acid exchange from valine to methionine. This altered protein provides further alternatives for expressing a functional GLUT4 protein. A
GLUT4 protein should be regarded as functional in connection with Saccharomyces cerevisiae if glucose uptake can be observed in a Saccharomyces cerevisiae strain whose glucose transporters in their entirety are inactive (=hxt(-)) after expression of I
said GLUT4 protein. Glucose uptake may be determined either by transport measurements by means of radioactively labeled glucose or by growth on medium with glucose as sole carbon source.

In a preferred embodiment, the purified and isolated polynucleotide comprising a DNA sequence which calls for a protein GLUT4V85M may include or comprise a sequence of the following groups:
a) a nucleotide sequence according to Seq ID No. 1, b) a nucleotide sequence which hybridizes to a sequence of Seq ID No. 1 under stringent conditions and which codes for a protein GLUT4V85M.

The purified and isolated polynucleotide preferably encodes a GLUT4V85M
protein which has an amino acid sequence of Seq ID No. 2.
The purified and isolated polynucleotide comprising a DNA sequence which codes as discussed previously for a protein GLUT4V85M, may be operationally linked to a promotor. Suitable promotors are in particular prokaryotic or eukaryotic promoters such as, for example, the Lac-, trp-, ADH- or HXT7 promotor. The part of the polynucleotides, which codes for the protein GLUT4V85M is operationally linked to a promotor precisely if a bacterial or eukaryotic organism produces, by means of said promotor with the aid of a vector, an mRNA which can be translated into the protein GLUT4V85M. An example of such a vector is the vector p4H7GLUT4V85M (Seq ID
No. 3). The protein GLUT4V85M may be expressed in yeast cells by means of said vector.
The above-described polynucleotide comprising a DNA sequence which codes for a protein GLUT4V85M is, in a preferred embodiment, suitable for replicating said polynucleotide in a yeast cell or for expressing the part of the polynucleotide, which encodes the protein GLUT4V85M, in a yeast cell to give the protein GLUT 4 V85M.
A yeast cell from Saccharomyces cerevisiae is particularly suitable. For replication and expression in a yeast cell, the polynucleotide comprising a DNA sequence which calls for a protein GLUT4V85M is present in the form of a yeast vector. The polynucleotide region coding for the GLUT4V85M protein may be operationally linked to a yeast cell-specific promotor such as, for example, the ADH
promotor (alcohol dehydrogenase promotor) or the HXT7 promotor (hexose-transporter promotor). The yeast sectors are a group of vectors which was developed for cloning of DNA in yeasts.

The invention furthermore relates to a yeast cell from Saccharomyces cerevisiae in which all glucose transporters are no longer functional (=hxt (-)) and which contains no functional Erg4 protein. Such a yeast cell is preferably a yeast cell deposited as Saccharomyces cerevisiae DSM 15187 with the DSMZ (Deutsche Sammlung von Mikroorganismen and Zelikulturen GmbH, Mascheroder Weg 16, 38124 Brunswick, Germany).
The invention also relates to a yeast cell in which all glucose transporters are no longer functional and which contains no functional Fgyl and no functional Erg4 protein. The lack of an Erg4 protein or of an Fgy1 protein may be attributed in particular to an interruption of the corresponding coding genome sections or to a partial or complete removal of said coding genome sections.
Preference is given to using as yeast cell which contains no functional glucose transporters, no functional Fgyl protein and no functional Erg4 protein, a yeast cell as deposited with the DSMZ as Saccharomyces cerevisiae DSM 15184.
A yeast cell as described above is preferably used for expressing a mammalian GLUT1 protein or a mammalian GLUT4 protein, in particular a protein from rats, mice, rabbits, pigs, cattle or primates. A preferred embodiment uses the yeast cell for expressing a human GLUT4 or GLUTI protein.
A Saccharomyces cerevisiae yeast cell whose glucose transporters in their entirety and also the Erg4 protein are no longer functional may contain a polynucleotide of the present invention, which comprises a DNA sequence coding for a protein GLUT4V85M. Said yeast cell can also express the GLUT4V85M protein and thus contain said protein.
A yeast strain of this kind, containing a polynucleotide which comprises a DNA, sequence coding for the GLUT4V85M protein, is preferably the Saccharomyces cerevisiae DSM 15185 yeast strain which has been deposited with the DMSZ.
A yeast cell whose glucose transporters in their entirety and also the Erg4 protein are no longer functional and which contains a polynucleotide comprising a DNA
sequence which calls for a protein GLUT4V85M may be prepared, for example, by a) providing a yeast cell whose glucose transporters in their entirety and also the Erg4 protein are no longer functional, b) providing an isolated and purified polynucleotide which comprises a DNA
sequence coding for the GLUT4V85M protein and which can be replicated in the yeast cell, c) transforming the yeast cell from a) with the polynucleotide from b), d) selecting a transformed yeast cell, e) where appropriate expressing the GLUT4V85M protein.

An isolated and purified polynucleotide which comprises a DNA sequence coding for 5 the GLUT4V85M protein is preferably a vector which can be replicated in a yeast cell and in which said DNA sequence was cloned. An example of such a vector is p4H7GLUT4V85M (Seq ID No. 3).

The invention also relates to a yeast cell whose glucose transporters in their entirety and whose proteins for Fgyl and Erg4 are no longer functional and which contains a polynucleotide which comprises a DNA sequence coding for the GLUT4V85M
protein. Said yeast cell can also express the GLUT4V85M protein and thus contain said protein. A yeast strain of this kind is preferably the Saccharomyces cerevisiae DSM 15186 deposited with the DSMZ.
A yeast cell whose glucose transporters in their entirety and also the proteins Fgyl and Erg4 are no longer functional and which contains a polynucleotide comprising a DNA sequence which codes for the GLUT4V85M protein may be prepared, for example, by a) providing a yeast cell whose glucose transporters in their entirety and also the proteins Fgyl and Erg4 are no longer functional, b) providing an isolated and purified polynucleotide which comprises a DNA
sequence coding for the GLUT4V85M protein and which can be replicated in the yeast cell, c) transforming the yeast cell from a) with the polynucleotide from b), d) selecting a transformed yeast cell, e) where appropriate expressing the GLUT4V85M protein.

The abovementioned isolated and purified polynucleotide which comprises a DNA
sequence coding for the GLUT4V85M protein is preferably a vector which can be replicated in a yeast cell and in which said DNA sequence was cloned. An example of such a vector is p4H7GLUT4V85M (Seq ID No. 3).

The invention also relates to a yeast cell whose glucose transporters in their entirety are no longer functional and which contains a polynucleotide comprising a DNA
sequence which calls for the GLUT4V85M protein.
Said yeast cell can also express the GLUT4V85M protein and thus contain said protein. A preferred yeast strain of this kind is the Saccharomyces cerevisiae yeast strain deposited with the DSMZ.

A yeast cell whose glucose transporters in their entirety are no longer functional and which contains a polynucleotide comprising a DNA sequence which codes for the GLUT4 V85M protein may be prepared, for example, by a) providing a yeast cell whose glucose transporters in their entirety are no longer functional, b) providing an isolated and purified polynucleotide which comprises a DNA
sequence coding for the GLUT4V85M protein and which can be replicated in the yeast cell, c) transforming the yeast cell from a) with the polynucleotide from b), d) selecting a transformed yeast cell, e) where appropriate expressing the GLUT4V85M protein.

An isolated and purified polynucleotide which comprises a DNA sequence coding for the GLUT4V85M protein is preferably a vector which can be replicated in a yeast cell and in which said DNA sequence was cloned. An example of such a vector is p4H7GLUT4V85M (Seq ID No. 3).
The invention also relates to a protein having the amino acid sequence according to Seq ID No. 2. Said protein is a human GLUT4 protein in which a valine has been replaced by a methionine in position 85 of the amino acid chain.

The invention also relates to a method for identifying a compound which stimulates the activity of a GLUT4 protein, which method comprises the steps a) providing a yeast cell whose glucose transporters in their entirety and also Erg4 protein are no longer functional and which contains a polynucleotide comprising a DNA sequence which codes for a protein GLUT4V85M, b) providing a chemical compound, c) contacting the yeast of a) with the chemical compound of b), d) determining glucose uptake by the yeast of c), e) relating the detected value of the glucose uptake of d) to the detected value of glucose uptake in a yeast cell as claimed in a) which has been contacted with a chemical compound as claimed in b), with a compound which causes an increase in the amount of glucose taken up in the yeast as claimed in d) stimulating the activity of said GLUT4 protein. Compounds which stimulate the activity of the GLUT4V85M protein can be assumed to stimulate also the GLUT4 activity.

The invention also relates to a pharmaceutical which contains a compound which has been identified by the method described above and furthermore to additives and excipients for formulating a pharmaceutical. Furthermore, the invention relates to the use of a compound which has been identified by the method described above for producing a pharmaceutical for the treatment of type I and/or II diabetes.
The invention also relates to a pharmaceutical comprising a compound which has been identified by the method described above and to additives and excipients for formulating a pharmaceutical. Furthermore, the invention relates to the use of a compound identified by the method described above for producing a pharmaceutical for the treatment of diabetes.

The invention furthermore relates to the use of a compound identified by a method described above for producing a pharmaceutical for the treatment of diabetes.
r' The present invention also comprises a method for identifying a compound which inhibits the protein encoded by the Erg4 gene, which method comprises the steps:
a) providing a yeast cell whose glucose transporters in their entirety and no longer functional and which contains a polynucleotide comprising a DNA
sequence which codes for the GLUT4V85M protein and can be replicated in a yeast cell, b) providing a chemical compound c) contacting the yeast of a) with the chemical compound of b), d) determining glucose uptake by the yeast of c), e) relating the detected value of the glucose uptake of d) to the detected value of glucose uptake in a yeast cell as claimed in a) which is not contacted with a chemical compound as claimed in b), with a compound which causes an increase in the amount of glucose taken up in the yeast as claimed in d) stimulating the activity of a protein Erg4.

The invention furthermore relates to a method for identifying a compound inhibiting the corresponding protein of the Fgyl gene, which comprises the steps:
a) providing a yeast cell whose glucose transporters in their entirety and whose Erg4 protein are no longer functional and which contains a GLUT4 protein, b) providing a chemical compound c) contacting the yeast of a) with the chemical compound of b), d) determining glucose uptake by the yeast of c), e) relating the detected value of the glucose uptake of d) to the detected value of glucose uptake in a yeast cell as claimed in a) which is not contacted with a chemical compound as claimed in b), with a compound which causes an increase in the amount of glucose taken up in the yeast as claimed in d) stimulating the activity of a protein Fgyl.

The invention also relates to a pharmaceutical comprising a compound which has been identified by the method described above and to additives and excipients for formulating a pharmaceutical.

The invention may be illustrated in more detail below with respect to technical details.
r Hybridization means the assembling of two nucleic acid single strands having complementary base sequences to double strands. Hybridization may take place between two DNA strands, one DNA and one RNA strand and between two RNA
strands. In principle, it is possible to prepare hybrid molecules by heating the nucleic acids involved which may initially be in double-stranded form, by boiling, for example, in a waterbath for 10 minutes, until they disintegrate into single-stranded molecules without secondary structure. Subsequently, they can be cooled slowly.
During the cooling phase, complementary chains pair to give double-stranded hybrid molecules. Under laboratory conditions, hybridizations are usually carried out with the aid of hybridization filters to which single-stranded or denaturable polynucleotide molecules are applied by blotting or electrophoresis. It is possible to visualize the hybridization using appropriate complementary polynucleotide molecules by providing said polynucleotide molecules to be hybridized with a radioactive fluorescent label. Stringency describes the degree of matching or alignment of particular conditions. High stringency has higher demands on matching than low stringency. Depending on the application and objective, particular conditions with different stringency are set for the hybridization of nucleic acids. At high stringency, the reaction conditions for the hybridization are set in such a way that only complementary molecules which match very well can hybridize with one another.
Low stringency enables molecules also to partially hybridize with relatively large sections of unpaired or mispaired bases.

The hybridization conditions are to be understood as being stringent, in particular, if the hybridization is carried out in an aqueous solution containing 2 x SSC at 68 C for at least 2 hours, followed by washing first in 2x SSC/0.1 % SDS at room temperature for 5 minutes, then in 1 x SSC/0.1 % SDS at 68 C for 1 hour and then in 0.2%
SSC/0.1% SDS at 68 C for another hour.

A 2 x SSC, 1 x SSC or 0.2 x SSC solution is prepared by diluting a 20 x SSC
solution appropriately. A 20 x SSC solution contains 3 mol/I NaCl and 0.3 mol/I Na citrate. The pH is 7Ø The skilled worker is familiar with the methods for hybridizations of polynucleotides under stringent conditions. Appropriate instructions can be found in specialist books such as, in particular, Current Protocols in Molecular Biology (Wiley Interscience; editors: Frederich M. Ausubel, Roger Brant, Robert E. Kingston, David J. Moore, J. G. Seidmann, Kevin Struhl; ISBN: 0-471-50338-X).

The yeast vectors can be divided into different subgroups. Ylp vectors (yeast integrating plasmids) essentially correspond to the vectors used in bacteria for clonings, but contain a selectable yeast gene (e.g. URA3, LEU2).
Only when the foreign DNA integrates into a yeast chromosome after introduction of said vector, are these sequences replicated together with the chromosome and, with the formation of a clone, stably transferred to all daughter cells.

Based on this method, plasmids have been derived which can replicate autonomously owing to eukaryotic ORIs (origins of replication). Such yeast vectors are referred to as YRp vectors (yeast replicating plasmids) or ARS vectors (autonomously replicating sequence). Furthermore, there are YEp vectors (yeast 5 episomal plasmids) which are derived from the yeast 2 m plasmid and which contain a selective marker gene. The class of the YAC vectors (yeast artificial chromosome) behave like independent chromosomes.

A yeast vector containing a gene to be expressed is introduced into the yeast by 10 means of transformation in order for said gene to be able to be expressed.
Examples of methods suitable for this purpose are electroporation or incubation of competent cells with vector DNA. Suitable yeast expression promoters are known to the skilled worker, examples being the SODI promotor (superoxide dismutase), ADH promotor (alcohol dehydrogenase), the promotor of the gene for acidic phosphatase, HXT2 promotor (glucose transporter 2), HXT7 promotor (glucose transporter 7), GAL2 promotor (galactose transporter) and others. The construct comprising a yeast expression promotor and a gene to be expressed (e.g. GLUT4V85M) is, for the purpose of expression, part of a yeast vector. To carry out expression, said yeast vector may be a self-replicating particle which is independent of the yeast genome or may be stably integrated into the yeast genome. A suitable yeast vector is in principle any polynucleotide sequence which can be propagated in a yeast.
Yeast vectors which may be used are in particular yeast plasmids or yeast artificial chromosomes. Yeast vectors usually contain an origin of replication (2 , ars) or1 starting the replication process and a selection marker which usually comprises an auxotrophy marker or an antibiotic resistance gene. Examples of yeast vectors known to the skilled worker are pBM272, pCS19, pEMBCYe23, pFL26, pG6, pNN414, pTV3, p426MET25, p4H7 and others.

In accordance with the present invention, selection of a cell means the specific concentration thereof, owing to a selection marker such as, for example, resistance to an antibiotic or the ability to grow on a particular minimal medium, and furthermore the isolation and subsequent cultivation thereof on an agar plate or in submerged culture.

Cultivation, transformation and selection of a transformed yeast cell and also expression of a protein in a yeast cell are among the methods commonly used by the skilled worker. Instructions regarding said methods can be found in standard text books, for example in Walker Graeme M.: Yeast Physiology and Biotechnology, Wiley and Sons, ISBN: 0-471-9446-8 or in Protein Synthesis and Targeting in Yeast, Ed. Alistair J. P. Brown, Mick F. Fruite and John E. G. Mc Cartly; Springer Berlin;
ISBN: 3-540-56521-3 or in "Methods in Yeast Genetics, 1997: A Cold Spring Harbor Laboratory Course Manual; Adams Alison (Edt.); Cold Spring Harbor Laboratory;
ISBN: 0-87969-508-0".

The yeast Saccharomyces cerevisiae has 17 known hexose transporters and additionally three known maltose transporters, which are capable of transporting hexoses into said yeast, provided that their expression is sufficiently high.
In one known strain all transporters suitable for hexose uptake were removed by deletion.
Said strain contains merely just the two genes MPH2 and MPH3 which are homologous to maltose transport proteins. The two genes MPH2 and MPH3 are repressed in the presence of glucose in the medium. Wieczorke et al., FEBS
Left.
464, 123 - 128 (1999) describe the preparation and characterization of this yeast strain. Said strain is not able to propagate on a substrate containing glucose as sole carbon source. It is possible to select from said strain mutants which functionally express GLUT1, starting from a corresponding vector (hxt fgyl -1 strain).
If the yeast strain hxt fgyl-1 is transformed with a plasmid vector which carries a GLUT4 gene under control of a yeast promotor, still only very little glucose is transported. Functional GLUT4 expression requires further adjustments to this yeast strain in order to make possible a significant glucose transport by means of GLUT4.
Such yeast strains whose cells take up glucose by means of a single glucose transporter GLUT4 can be isolated on substrates having glucose as sole carbon source. For this purpose, a yeast hxt fgyl-1 strain carrying a GLUT4 gene under the functional control of a yeast promotor is transformed. These yeast cells transformed in this way are applied to a nutrient medium containing glucose as sole carbon source and are incubated thereon. After a few days of incubation at, for example 30 C, the growth of individual colonies is observed. One of these colonies is isolated.
The removal of the yeast plasmid from said colony prevents propagation on the nutrient medium containing glucose as sole carbon source. If this strain which no longer contains a vector plasmid is again transformed with a yeast vector carrying a GLUT4 gene under the functional control of a yeast promotor, said strain is then again able to propagate on a medium containing glucose as sole carbon source.
The abovementioned yeast strains are the subject matter of International Application PCT/EP02/01373, filed on February 9, 2002, which claims the priority of DE
10106718.6 of February 14, 2002.

Yeast strains whose indigenous transporters for hexoses (glucose transporters) in their entirety are no longer functional have already been deposited at an earlier date in connection with International Application PCT/EP02/01373 with the Deutsche Sammiung von Mikroorganismen and Zellkulturen GmbH (DSMZ) under the number DSM 14035, DSM 14036 or DSM 14037.
The polynucleotide and amino acid sequences of GLUT4 are accessible, for example, via the following entries in gene banks: M20747 (cDNA; human), EMBL:
D28561 (cDNA; rat), EMBL: M23382 (cDNA; mouse), Swissprot: P14672 (protein;
human), Swissprot: P19357 (protein; rat) and Swissprot: P14142 (protein;
mouse).
Polynucleotide sequences and amino acid sequences of GLUT1 are disclosed under the following code numbers of the databases indicated: EMBL: M20653 (cDNA;
human), EMBL: M13979 (cDNA; rat), EMBL: M23384 (cDNA; mouse), Swissprot:
P11166 (protein; human), Swissprot: P11167 (protein; rat) and Swissprot:

(protein; mouse).

Pharmaceuticals are dosage forms of pharmacologically active substances for the therapy of diseases or bodily malfunctions in humans and animals. Examples of dosage forms for oral therapy are powders, granules, tablets, pills, lozenges, sugar-coated tablets, capsules, liquid extracts, tinctures and syrups. Examples which are used for external application are aerosols, sprays, gels, ointments or powders.
Injectable or infusible solutions allow parenteral administration, using vials, bottles or prefilled syringes. These and other pharmaceuticals are known to the skilled worker in the field of pharmaceutical technology.

Excipients for formulating a pharmaceutical made possible the preparation of the active substance with the purpose of optimizing the application, distribution and development of action of the active ingredient for the particular application.
Examples of such excipients are fillers, binders, disintegrants or glidants, such as lactose, sucrose, mannitol, sorbitol, cellulose, starch, dicalcium phosphate, polyglycols, alginates, polyvinylpyrrolidone, carboxymethylcellulose, talc or silicon dioxide.

Diabetes manifests itself by the excretion of glucose together with the urine with an abnormal increase in the blood glucose level (hyperglycaemia), owing to a chronic metabolic condition due to insulin deficiency or reduced insulin action. The lack of, or reduced, insulin action leads to insufficient absorption and conversion by the cells of the glucose taken up into the blood. In fatty tissue, insulin-antagonistic hormones have the effect of increasing lypolysis accompanied by an increase in the free fatty acid levels in the blood.

Adiposity (obesity) is the abnormal weight gain owing to an energy imbalance due to excessive intake of calories, which constitutes a health risk.
The amount of a hexose which is taken up by a provided yeast strain as described just above can be determined by means of uptake studies using radioactively labeled glucose. For this purpose, a particular concentration of the yeast cells is suspended in, for example, 100 I of a buffer, for example at a concentration of 60 mg (wet weight) per ml, and admixed with a defined amount of 14C- or 3H-labeled glucose as sole carbon source. The cells are incubated, and defined amounts thereof are removed at specific times. The amount of glucose taken up is determined with the aid of LSC (Liquid Scintillation Counting). The amount of a hexose which is taken up by a yeast strain provided and as just described above may, however, also be determined by means of a growth assay on media containing glucose as sole carbon source. For this purpose, the rate of growth of the strain is determined, after addition of the compound, for example by measuring the optical density of the culture at 600 nm at regular intervals, and this value is compared with the rate of growth of a control strain (e.g. yeast wild-type strain).

A compound is provided, in particular, by chemical synthesis or by isolating chemical substances from biological organisms. It is also possible to carry out chemical synthesis in an automated manner. The compounds obtained by synthesis or isolation can be dissolved in a suitable solvent. Suitable solvents are in particular aqueous solutions which contain a specific proportion of an organic solvent such as, for example, DMSO (dimethylsulfoxide).
Conducting a strain of the yeast with a compound for identifying a compound in accordance with an invention mentioned above is done in particular in automated laboratory systems provided therefor. Such systems may comprise specifically prepared chambers with depressions, or microtiter plates, Eppendorf tubes or laboratory glassware. Automated laboratory systems are usually designed for high throughput rates. A method such as the one mentioned above, carried out with the aid of an automated laboratory system, is therefore also referred to as HTS
(High Throughput Screening).

Seq ID No. 1 discloses a polynucleotide sequence comprising the coding region of the GLUT4V85M protein. Seq ID No. 2 discloses the amino acid sequence of the GLUT4V85M protein. Seq ID No. 3 discloses the polynucleotide sequence of the p4H7GLUT4V85M vector.

Examples Use of yeast strains All of the yeast strains described herein were derived from strain CEN-PK2-1 C
(MATa leu2-3, 112 ura3-52 trpl-289 his3-A1 MAL2-8 SUC2). The preparation of a yeast strain having deletions in the hexose transporter genes (HXT) has been described by Wieczorke et al., FEBS Lett. 464, 123 - 128 (1999): EBY-18ga (MATa Ahxt1-17 Aga12 Dagt1 Asti1 leu2-3, 112 ura3-52 trpl -289 his3-M1 MAL2-8c SUC2), EBY.VW4000 (MATa Ohxt1-17 Aga12 Eagt1 Amph2 Amph3 OstI1 Ieu2-3, 112 ura3-52 trpl-289 his3-01 MAL2-8` SUC2). The media were based on 1% yeast extract and 2% peptone (YP), while the minimal media were composed of 0.67% Difco yeast nitrogen base without amino acids (YNB) and contained additives required for auxotrophy and different carbon sources. The yeast cells were grown under aerobic 5 conditions at 30 C on a rotary shaker or on agar plates. Cell growth was monitored by measuring the optical density at 600 nm (OD600) or by determining the diameter of yeast colonies.

10 Determination of glucose uptake Glucose transport was measured as uptake of D-[U-14C1-glucoses (Amersham) and the kinetic parameters were determined from Eadie-Hofstee plots. The cells were removed by centrifugation, washed with phosphate-buffer and resuspended in phosphate buffer at a concentration of 60 mg (wet weight) per ml. Glucose uptake 15 was determined for glucose concentrations between 0.2 and 100 mM, and the specific activity of the substrate was between 0.1 and 55.5 kBq mol"1. The cells and the glucose solutions were preincubated at 30 C for 5 minutes. Glucose uptake was started by adding radioactive glucose to the cells. After incubation for 5 seconds, 10 ml of ice-cold stop buffer (0.1 M KiPO4, pH 6.5, 500 mM glucose) were added and the cells were removed quickly by filtering on glass fiber filters (0 = 24 mm, Whatman). The filters were quickly washed three times with ice-cold buffer and the radioactivity incorporated was measured using a liquid scintillation counter.
An addition by cytochalasin B (final concentration 20 M, dissolved in ethanol) was,-measured in a 15-second uptake assay with 50 mM or 100 mM radioactive glucose, after the cells had been incubated in the presence of the inhibitor or of only the solvent for 15 minutes.

A novel heterologous expression system for glucose transporters from mammalian cells has been developed. The system is based on an S. cerevisiae strain from which all endogenous glucose transporters have been removed destroying the encoding genes. Said strain is no longer able to take up glucose via the plasma membrane and to grow with glucose as sole carbon source. In order to integrate the heterologous glucose transporters of humans or of other mammals, GLUT1 and GLUT4 in an active form into the yeast plasma membrane, additional mutations had to be introduced into the yeast strain. GLUT1 is active only in an fgyl-1 mutant strain and GLUT4 only in fgyl-1 fgy4-X double mutants.

The FGY1 gene has been cloned. It is the S. cerevisiae ORF YMR212c. With respect to the function, the results indicate that either Fgyl or a product generated by Fgyl inhibits the activity of human glucose transporters or is involved in fusing the GLUT-transporting vesicles to the plasma membrane.

In contrast to GLUT1 and similarly to mammalian cells, a large proportion of the GLUT4 proteins in the yeast is located in intracellular structures. A total of nine recessive mutants were isolated (fgy4-1 to fgy4-9) in which GLUT4 is now directed further to the plasma membrane and, in the case of a concomitant fgyl-1 mutation, becomes active there.
The insertion gene bank described by Bruns et al. (Genes Dev. 1994; 8: 1087-105) was used for complementation analysis. The hxt fgyl -1 strain was transformed first with a GLUT4 plasmid and then with the mobilized insertion gene bank. This was followed by screening for transformants which were able to grow on glucose medium. It turned out that in one of the mutants studied the ERG4 gene had been destroyed. ERG4 codes for an enzyme (oxidoreductase) of ergosterol biosynthesis.
This enzyme, sterol C-24(28)-reductase catalyzes the last step of ergosterolbiosynthesis and converts ergosta-5,7,22,24,(28)-tetraenol to the final product ergosterol. The Erg4 protein presently contains eight transmembrane domains and is located in the endoplasmic reticulum. An erg4 mutant is viable, since incorporation of the ergosterol precursors into the yeast membranes compensates for the loss of ergosterol.

The inhibiting influence of Erg4 on GLUT4 functionality was confirmed by specific deletion of erg4 in the hxt fgyl-1 strain. The resulting strain (hxt fgyl-1 Aerg4) was referred to as SDY022.
Protein interaction assays with the aid of the split-ubiquitin system showed that human GLUT4 directly interacts with yeast Erg4. It can therefore be assumed that the yeast Erg4 protein in the endoplasmic reticulum either directly prevents further translocation of GLUT4 or modifies GLUT4 in some way which is important for translocation and/or function.

Likewise, it was shown that deletion of ERG4 in the hxt null strain alone, i.e. despite functional FGY1, activates GLUT1, but not GLUT4. The results of the growth assay are summarized in Table 1.

In order to rule out that Ergosterol itself exerts a negative influence on GLUT4, growth assays were carried out on agar plates containing Ergosterol under aerobic conditions. Any yeast strains transformed with GLUT4 were unable to grow under these conditions (Table 2). The GLUT1 transformants in the hxt fgyl-1 strain showed, in contrast to aerobic growth, no growth on glucose under anaerobic conditions. GLUT1 transformants were able to grow only after deletion of ERG4.
The exchange of Va185 for Met by in vitro mutagenesis rendered GLUT4 independent of the fgyl -1 mutation and resulted in GLUT4V85M being functional even in an hxt erg4 strain. This observation indicates that Fgy1 acts directly or indirectly on this position which is located within the second transmembrane helix of GLUT transporters.

Table 3 displays the descriptions of the yeast strains deposited in connection with the present patent application with the Deutsche Sammlung von Mikroorganisnen and Zellkulturen (DSMZ) - Mascheroder Weg 1 b 38124 Brunswick, Germany.
Table 1: Growth of GLUTI and GLUT4 transformants on glucose medium.
Genotype I % Glucose I % Glucose Ahxt fgy1-1 GLUT4 - GLUT1 ++
Ahxt fgyl-1 Aerg4 GLUT4 ++ GLUT1 ++
Ohxt fgyl-1 Derg4 Vector - Vector -Ohxt fgyl-1 Aerg5 GLUT4 - GLUT1 ++
Ohxt fgyl-1 Aerg4 Derg5 GLUT4 + GLUT1 ++

Ahxt Eerg4 GLUT4 - GLUT1 \hxt oerg5 GLUT4 - GLUT1 -Table 2: Growth of GLUT1 and GLUT4 transformants on glucose medium with or without ergosterol under anaerobic conditions 1 % Glucose+
Genotype 1 % Glucose 33 mg/I Ergosterol Ahxt fgyl-1 GLUT1 - -Ahxt fgyl-1 derg4 GLUT1 - ++

Ahxt fgy1-1 Aerg5 GLUT1 - -Lihxt fgyl-1 Aerg4 Derg5 GLUT1 - ++

Ahxt Derg4 GLUT1 - (+) Ahxt ierg5 GLUT1 - -Table 3: Features of the deposited yeast strains (Saccharomyces cerevisiae) Number of Genotype Phenotype Plasmid deposit with the DSMZ
DSM 15187 MATa Ahxtl-17 AgaI2 Strain growth with -Dagt1 Ostll omph2 1 % maltose as omph3 Lerg4 leu2-3, carbon source;
112 ura3-52 trpl-289 auxotrophic for his3-01 MAL2-8c SUC2 glucose, leucine, tryptophan, histidine and uracil DSM 15184 MATa Ahxtl -17 Aga12 Strain growth with -oagtl ostl1 Aerg4 fgyl - 1 % maltose as 1 leu2-3, 112 ura3-52 carbon source;
trpl-289 his3-01 MAL2- auxotrophic for 8c SUC2 glucose, leucine, tryptophan, histidine and uracil DSM 15185 MATa Ohxt1-17 Aga12 Strain growth with p4H7GLUT4V85M
Dagtl ostll Amph2 1 % maltose as (Selection marker Amph3 Derg4 leu2-3, carbon source; URA3), 112 ura3-52 trpl-289 auxotrophic for = Seq ID No. 3 his3-M1 MAL2-8c SUC2 glucose, leucine, tryptophan and histidine DSM 15186 MATa Ohxt1-17 Aga12 Strain growth with p4H7GLUT4V85M
Dagtl Estil Aerg4 fgyl- 1% maltose as (Selection marker 1 leu2-3, 112 ura3-52 carbon source; URA3) trpl-289 his3-o1 MAL2- auxotrophic for = Seq ID No. 3 8c SUC2 glucose, leucine, tryptophan and histidine DSM 15188 MATa Ohxt1-17 Aga12 Strain growth with p4H7GLUT4V85M
Aagtl AstIl Omph2 1 % maltose as (Selection marker omph3 leu2-3, 112 carbon source; URA3) ura3-52 trpl -289 his3- auxotrophic for = Seq ID No. 3 Al MAL2-8c SUC2 glucose, leucine, tryptophan and histidine Basic medium: 0.67% Yeast Nitrogen Base without amino acids (Difco); pH 6.2.
Auxotrophy supplementation: Leucine (0.44 mM), tryptophan (0.19 mM), histidine (0.25 mM9, uracil (0.44 mM). Maltose may be between 1-2%.

BUDAPEST TREATY ON THE INTERNATIONAL DSMZ
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS Deutsche Sammlung FOR THE PURPOSES OF PATENT PROCEDURE von Mikroorganismen and Zellkulturen GmbH
INTERNATIONAL FORM

Aventis Pharma Deutschland GmbH
Industriepark H6chst RECEIPT IN THE EVENT OF AN ORIGINAL DEPOSIT
D-65926 Frankfurt issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page 1. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the ACCESSION NUMBER issued by DEPOSITOR: the INTERNATIONAL DEPOSITARY AUTHORITY:
DSMefg DSM 15185 II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION
The microorganism identified in section I was accompanied by:

a scientific description a proposed taxonomic designation (Indicate as applicable) III. RECEIPT AND ACCEPTANCE

The present International Depositary Authority accepts the microorganism identified in section I, which it received on 2002-09-03 (date of the original deposit)' IV. RECEIPT OF A REQUEST FOR CONVERSION

The present International Depositary Authority received the microorganism identified under section I on (date of the original deposit) and received a request for conversion of the original deposit to a deposit conforming to the Budapest Treaty on (date of receipt of the request for conversion) V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of the person(s) having the power to represent MIKROORGANISMEN UND ZELLKULTUREN GmbH the International Depositary Authority, or of authorized Address: Mascheroder Weg 1b official(s) (illegible signature) D-38124 Brunswick Date: 2002-09-10 ' If Rule 6.4.d) applies, this date shall be the date on which the status of the international depositary authority was acquired.

Form DSMZ-BP/4 (single page) 12/2001 BUDAPEST TREATY ON THE INTERNATIONAL DSMZ
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS Deutsche Sammlung FOR THE PURPOSES OF PATENT PROCEDURE von Mikroorganismen and Zellkulturen GmbH
INTERNATIONAL FORM

Aventis Pharma Deutschland GmbH
Industriepark HOchst VIABILITY STATEMENT
D-65926 Frankfurt issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page 1. DEPOSITOR II. IDENTIFICATION OF THE MICROORGANISM
Name: Aventis Pharma Deutschland GmbH
Industriepark HOchst ACCESSION NUMBER given by the INTERNATIONAL DEPOSITARY AUTHORITY:
Address: D-65926 Frankfurt DSM 15185 Date of the deposit or of the transfer':

III. VIABILITY STATEMENT

The viability of the microorganism identified under section II above was tested on 2002-09-062. On that date, the said microorganism was 3 viable ^3 no longer viable IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED4 V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of the person(s) having the power to represent MIKROORGANISMEN UND ZELLKULTUREN GmbH the International Depositary Authority, or of authorized official(s) Address: Mascheroder Weg 1 b D-38124 Brunswick (illegible signature) Date: 2002-09-10 ' Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the date of the most recent relevant new deposit or transfer.
2 In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.
3 Mark with a cross the applicable box.
4 Fill in if the information has been requested and if the results of the test were negative.
Form DSMZ-BP/9 (single page) 12/2001 BUDAPEST TREATY ON THE INTERNATIONAL DSMZ
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS Deutsche Sanunlung FOR THE PURPOSES OF PATENT PROCEDURE von Mikroorganismen and Zellkulturen GmbH
INTERNATIONAL FORM

Aventis Pharma Deutschland GmbH
Industriepark H6chst RECEIPT IN THE EVENT OF AN ORIGINAL DEPOSIT
D-65926 Frankfurt issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page 1. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the ACCESSION NUMBER issued by DEPOSITOR: the INTERNATIONAL DEPOSITARY AUTHORITY:
DSMhij DSM 15186 II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION
The microorganism identified in section I was accompanied by:

a scientific description a proposed taxonomic designation (Indicate as applicable) III. RECEIPT AND ACCEPTANCE

The present International Depositary Authority accepts the microorganism identified in section I, which it received on 2002-09-03 (date of the original deposit)' IV. RECEIPT OF A REQUEST FOR CONVERSION

The present International Depositary Authority received the microorganism identified under section I on (date of the original deposit) and received a request for conversion of the original deposit to a deposit conforming to the Budapest Treaty on (date of receipt of the request for conversion) V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of the person(s) having the power to represent MIKROORGANISMEN UND ZELLKULTUREN the International Depositary Authority, or of authorized GmbH official(s) Address: Mascheroder Weg 1b (illegible signature) D-38124 Brunswick Date: 2002-09-10 If Rule 6.4.d) applies, this date shall be the date on which the status of the international depositary authority was acquired.

Form DSMZ-BP/4 (single page) 12/2001 BUDAPEST TREATY ON THE INTERNATIONAL DSMZ
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS Deutsche Sanunlunc, FOR THE PURPOSES OF PATENT PROCEDURE von Mikroorganismen and Zellkulturen GmbH
INTERNATIONAL FORM

Aventis Pharma Deutschland GmbH
Industriepark H6chst VIABILITY STATEMENT
D-65926 Frankfurt issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page 1. DEPOSITOR II. IDENTIFICATION OF THE MICROORGANISM
Name: Aventis Pharma Deutschland GmbH
Industriepark H6chst ACCESSION NUMBER given by the INTERNATIONAL DEPOSITARY AUTHORITY:
Address: D-65926 Frankfurt DSM 15186 Date of the deposit or of the transfer:

III. VIABILITY STATEMENT

The viability of the microorganism identified under section II above was tested on 2002-09-062. On that date, the said microorganism was 3 viable ^3 no longer viable IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED4 V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of the person(s) having the power to represent MIKROORGANISMEN UND ZELLKULTUREN the International Depositary Authority, or of authorized GmbH official(s) Address: Mascheroder Weg 1 b (illegible signature) D-38124 Brunswick Date: 2002-09-10 1 Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the date of the most recent relevant new deposit or transfer.
2 In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.
3 Mark with a cross the applicable box.
4 Fill in if the information has been requested and if the results of the test were negative.
Form DSMZ-BP/9 (single page) 12/2001 BUDAPEST TREATY ON THE INTERNATIONAL DSMZ
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS Deutsche Sammlung FOR THE PURPOSES OF PATENT PROCEDURE von Mikroorganismen and Zellkulturen GmbH
INTERNATIONAL FORM

Aventis Pharma Deutschland GmbH
Industriepark H6chst RECEIPT IN THE EVENT OF AN ORIGINAL DEPOSIT
D-65926 Frankfurt issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page 1. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the ACCESSION NUMBER issued by DEPOSITOR: the INTERNATIONAL DEPOSITARY AUTHORITY:
DSMsyz DSM 15187 II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION
The microorganism identified in section I was accompanied by:
a scientific description a proposed taxonomic designation (Indicate as applicable) Ill. RECEIPT AND ACCEPTANCE

The present International Depositary Authority accepts the microorganism identified in section I, which it received on 2002-09-03 (date of the original deposit)' IV. RECEIPT OF A REQUEST FOR CONVERSION

The present International Depositary Authority received the microorganism identified under section I on (date of the original deposit) and received a request for conversion of the original deposit to a deposit conforming to the Budapest Treaty on (date of receipt of the request for conversion) V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of the person(s) having the power to represent MIKROORGANISMEN UND ZELLKULTUREN the International Depositary Authority, or of authorized GmbH official(s) Address: Mascheroder Weg 1b (illegible signature) D-38124 Brunswick Date: 2002-09-10 If Rule 6.4.d) applies, this date shall be the date on which the status of the international depositary authority was acquired.

Form DSMZ-BP/4 (single page) 12/2001 BUDAPEST TREATY ON THE INTERNATIONAL DSMZ
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS Deutsche Sammlung FOR THE PURPOSES OF PATENT PROCEDURE von Mikroorganismen and Zellkulturen GmbH
INTERNATIONAL FORM

Aventis Pharma Deutschland GmbH
Industriepark Hochst VIABILITY STATEMENT
D-65926 Frankfurt issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page 1. DEPOSITOR II. IDENTIFICATION OF THE MICROORGANISM
Name: Aventis Pharma Deutschland GmbH
Industriepark Hochst ACCESSION NUMBER given by the INTERNATIONAL DEPOSITARY AUTHORITY:
Address: D-65926 Frankfurt DSM 15187 Date of the deposit or of the transfer:

III. VIABILITY STATEMENT

The viability of the microorganism identified under section II above was tested on 2002-09-062. On that date, the said microorganism was 3 viable ^3 no longer viable IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED"
V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of the person(s) having the power to represent MIKROORGANISMEN UND ZELLKULTUREN the International Depositary Authority, or of authorized GmbH official(s) Address: Mascheroder Wag 1b (illegible signature) D-38124 Brunswick Date: 2002-09-10 Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the date of the most recent relevant new deposit or transfer.
2 In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.
3 Mark with a cross the applicable box.
4 Fill in if the information has been requested and if the results of the test were negative.
Form DSMZ-BP/9 (single page) 12/2001 BUDAPEST TREATY ON THE INTERNATIONAL DSMZ
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS Deutsche Sammlung FOR THE PURPOSES OF PATENT PROCEDURE von Mikroorganismen and Zellkulturen GmbH
INTERNATIONAL FORM

Aventis Pharma Deutschland GmbH
Industriepark H6chst RECEIPT IN THE EVENT OF AN ORIGINAL DEPOSIT
D-65926 Frankfurt issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page 1. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the ACCESSION NUMBER issued by DEPOSITOR: the INTERNATIONAL DEPOSITARY AUTHORITY:
DSMuvw DSM 15188 II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION
The microorganism identified in section I was accompanied by:
a scientific description a proposed taxonomic designation (Indicate as applicable) III. RECEIPT AND ACCEPTANCE

The present International Depositary Authority accepts the microorganism identified in section I, which it received on 2002-09-03 (date of the original deposit)' IV. RECEIPT OF A REQUEST FOR CONVERSION

The present International Depositary Authority received the microorganism identified under section I on (date of the original deposit) and received a request for conversion of the original deposit to a deposit conforming to the Budapest Treaty on (date of receipt of the request for conversion) V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of the person(s) having the power to represent MIKROORGANISMEN UND ZELLKULTUREN the International Depositary Authority, or of authorized GmbH official(s) Address: Mascheroder Weg 1b (illegible signature) D-38124 Brunswick Date: 2002-09-10 If Rule 6.4.d) applies, this date shall be the date on which the status of the international depositary authority was acquired.

Form DSMZ-BP/4 (single page) 12/2001 BUDAPEST TREATY ON THE INTERNATIONAL DSMZ
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS Deutsche Sammlung FOR THE PURPOSES OF PATENT PROCEDURE von Mikroorganismen and Zellkulturen GmbH
INTERNATIONAL FORM

Aventis Phamia Deutschland GmbH
Industriepark HBchst VIABILITY STATEMENT
D-65926 Frankfurt issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page 1. DEPOSITOR II. IDENTIFICATION OF THE MICROORGANISM
Name: Aventis Pharma Deutschland GmbH
Industriepark H6chst ACCESSION NUMBER given by the INTERNATIONAL DEPOSITARY AUTHORITY:
Address: D-65926 Frankfurt DSM 15188 Date of the deposit or of the transfer:

III. VIABILITY STATEMENT

The viability of the microorganism identified under section 11 above was tested on 2002-09-062. On that date, the said microorganism was 3 viable ^3 no longer viable IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED"
V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of the person(s) having the power to represent MIKROORGANISMEN UND ZELLKULTUREN the International Depositary Authority, or of authorized GmbH official(s) Address: Mascheroder Weg 1 b (illegible signature) D-38124 Brunswick Date: 2002-09-10 1 Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the date of the most recent relevant new deposit or transfer.
2 In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.
3 Mark with a cross the applicable box.
4 Fill in if the information has been requested and if the results of the test were negative.
Form DSMZ-BP/9 (single page) 12/2001 BUDAPEST TREATY ON THE INTERNATIONAL DSMZ
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS Deutsche Sammlung FOR THE PURPOSES OF PATENT PROCEDURE von Mikroorganismen and Zellkulturen GmbH
INTERNATIONAL FORM

Aventis Pharma Deutschland GmbH
Industriepark Hbchst RECEIPT IN THE EVENT OF AN ORIGINAL DEPOSIT
D-65926 Frankfurt issued pursuant to Rule 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page 1. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the ACCESSION NUMBER issued by DEPOSITOR: the INTERNATIONAL DEPOSITARY AUTHORITY:
DSMdef DSM 15184 II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION
The microorganism identified in section I was accompanied by:
a scientific description a proposed taxonomic designation (Indicate as applicable) III. RECEIPT AND ACCEPTANCE

The present International Depositary Authority accepts the microorganism identified in section I, which it received on 2002-09-03 (date of the original deposit)' IV. RECEIPT OF A REQUEST FOR CONVERSION

The present International Depositary Authority received the microorganism identified under section I on (date of the original deposit) and received a request for conversion of the original deposit to a deposit conforming to the Budapest Treaty on (date of receipt of the request for conversion) V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of the person(s) having the power to represent MIKROORGANISMEN UND ZELLKULTUREN the International Depositary Authority, or of authorized GmbH official(s) Address: Mascheroder Weg 1b (illegible signature) D-38124 Brunswick Date: 2002-09-10 ' If Rule 6.4.d) applies, this date shall be the date on which the status of the international depositary authority was acquired.

Form DSMZ-BP/4 (single page) 12/2001 BUDAPEST TREATY ON THE INTERNATIONAL DSMZ
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS Deutsche Sammlung FOR THE PURPOSES OF PATENT PROCEDURE von Mikroorganismen and Zellkulturen GmbH
INTERNATIONAL FORM

Aventis Pharma Deutschland GmbH
Industriepark H6chst VIABILITY STATEMENT
D-65926 Frankfurt issued pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page 1. DEPOSITOR II. IDENTIFICATION OF THE MICROORGANISM
Name: Aventis Pharma Deutschland GmbH
Industriepark HOchst ACCESSION NUMBER given by the INTERNATIONAL DEPOSITARY AUTHORITY:
Address: D-65926 Frankfurt DSM 15184 Date of the deposit or of the transfer:

III. VIABILITY STATEMENT

The viability of the microorganism identified under section 11 above was tested on 2002-09-062. On that date, the said microorganism was 3 viable ^3 no longer viable IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED4 V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of the person(s) having the power to represent MIKROORGANISMEN UND ZELLKULTUREN the International Depositary Authority, or of authorized GmbH official(s) Address: Mascheroder Weg 1b (illegible signature) D-38124 Brunswick Date: 2002-09-10 1 Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the date of the most recent relevant new deposit or transfer.
2 In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability test.
3 Mark with a cross the applicable box.
Fill in if the information has been requested and if the results of the test were negative.
Form DSMZ-BP/9 (single page) 12/2001 SEQUENCE LISTING
<110> Sanofi-Aventis Deutschland GmbH

<120> Use of saccharomyces cerevisiae ergo mutants for the expression of glucose transporters from mammals <130> 9982-875 <140> CA 2,498,636 <141> 2003-09-04 <150> 10242763.1 <151> 2002-09-14 <160> 3 <170> Patentln Ver. 2.1 <210> 1 <211> 1530 <212> DNA

<213> Homo sapiens <400> 1 atgccgtcgg gcttccaaca gataggctcc gaagatgggg aaccccctca gcagcgagtg 60 actgggaccc tggtccttgc tgtgttctct gcggtgcttg gctccctgca gtttgggtac 120 aacattgggg tcatcaatgc ccctcagaag gtgattgaac agagctacaa tgagacgtgg 180 ctggggaggc aggggcctga gggacccagc tacatccctc caggcaccct caccaccctc 240 tgggccctct ccatggccat cttttccgtg ggcggcatga tttcctcctt cctcattggt 300 atcatctctc agtggcttgg aaggaaaagg gccatgctgg tcaacaatgt cctggcggtg 360 ctggggggca gcctcatggg cctggccaac gctgctgcct cctatgaaat gctcatcctt 420 ggacgattcc tcattggcgc ctactcaggg ctgacatcag ggctggtgcc catgtacgtg 480 ggggagattg ctcccactca cctgcggggc gccctgggga cgctcaacca actggccatt 540 gttatcggca ttctgatcgc ccaggtgctg ggcttggagt ccctcctggg cactgccagc 600 ctgtggccac tgctcctggg cctcacagtg ctacctgccc tcctgcagct ggtcctgctg 660 cccttctgtc ccgagagccc ccgctacctc tacatcatcc agaatctcga ggggcctgcc 720 agaaagagtc tgaagcgcct gacaggctgg gccgatgttt ctggagtgct ggctgagctg 780 aaggatgaga agcggaagct ggagcgtgag cggccactgt ccctgctcca gctcctgggc 840 agccgtaccc accggcagcc cctgatcatt gcggtcgtgc tgcagctgag ccagcagctc 900 tctggcatca atgctgtttt ctattattcg accagcatct tcgagacagc aggggtaggc 960 cagcctgcct atgccaccat aggagctggt gtggtcaaca cagtcttcac cttggtctcg 1020 gtgttgttgg tggagcgggc ggggcgccgg atgctccatc tcctgggoet ggcgggcatg 1080 tgtggctgtg ccatcctgat gactgtggct ctgctcctgc tggagcgagt tccagccatg 1140 agctacgtct ccattgtggc catctttggc ttcgtggcat tttttgagat tggccctggc 1200 cccattcctt ggttcatcgt ggccgagctc ttcagccagg gaccccgccc ggcagccatg 1260 gctgtggctg gtttctccaa ctggacgagc aacttcatca ttggcatggg tttccagtat 1320 gttgcggagg ctatggggcc ctacgtcttc cttctatttg cggtcctcct gctgggcttc 1380 ttcatcttca ccttcttaag agtacctgaa actcgaggcc ggacgtttga ccagatctca 1440 gctgccttcc accggacacc ctctctttta gagcaggagg tgaaacccag cacagaactt 1500 gagtatttag ggccagatga gaacgactga 1530 <210> 2 <211> 509 <212> PRT

<213> Homo sapiens <400> 2 Met Pro Ser Gly Phe Gln Gln Ile Gly Ser Glu Asp Gly Glu Pro Pro 3s Gln Gln Arg Val Thr Gly Thr Leu Val Lou Ala Val Phe Ser Ala Val Leu Gly Ser Lou Gln Phe Gly Tyr Asn Ile Gly Val Ile Asn Ala Pro Gln Lys Val Ile Glu Gln Ser Tyr Asn Glu Thr Trp Leu Gly Arg Gln Gly Pro Glu Gly Pro Ser Ser Ile Pro Pro Gly Thr Leu Thr Thr Lou Trp Ala Leu Ser Met Ala Ile Phe Ser Val Gly Gly Met Ile Ser Ser Phe Leu Ile Gly Ile Ile Ser Gln Trp Leu Gly Arg Lys Arg Ala Met 100 105. 110 Leu Val Asn Asn Val Leu Ala Val Leu Gly Gly Ser Leu Met Gly Lou Ala Asn Ala Ala Ala Ser Tyr Glu Met.Leu Ile Lou Gly Arg Phe Lou Ile Gly Ala Tyr Ser Gly Leu Thr Ser Gly Leu Val Pro Met Tyr Val Gly Glu Ile Ala Pro Thr His Lou Arg Gly Ala Lou Gly Thr Leu Asn 3Lt Gln Leu Ala Ile Val Ile Gly Ile Leu Ile Ala Gln Val Leu Gly Leu Glu Ser Leu Leu Gly Thr Ala Ser Leu Trp Pro Leu Leu Leu Gly Leu Thr Val Leu Pro Ala Leu Leu Gln Leu Val Leu Leu Pro Phe Cys Pro Glu Ser Pro Arg Tyr Leu Tyr Ile Ile Gln Asn Leu Glu Gly Pro Ala Arg Lys Ser Leu Lys Arg Leu Thr Gly Trp Ala Asp Val Ser Gly Val Leu Ala Glu Leu Lys Asp Glu Lys Arg Lys Leu Glu Arg Glu Arg Pro Leu Ser Leu Leu Gln Leu Leu Gly Ser Arg Thr His Arg Gln Pro Leu Ile Ile Ala Val Val Leu Gln Leu Ser Gln Gln Leu Ser Gly Ile Asn Ala Val Phe Tyr Tyr Ser Thr Ser Ile.Phe Glu Thr Ala Gly Val Gly Gln Pro Ala Tyr Ala Thr Ile Gly Ala Gly Val Val Asn Thr Val Phe Thr Leu Val Ser Val Leu Leu Val Glu Arg Ala Gly Arg Arg Thr Leu His Leu Leu Gly Leu Ala Gly Met Cys'Gly Cys Ala Ile Leu Met Thr Val Ala Leu Leu Leu Leu Glu Arg Val Pro Ala Met Ser Tyr Val Ser Ile Val Ala Ile Phe Gly Phe Val Ala Phe Phe Glu Ile Gly Pro Gly Pro Ile Pro Trp Phe Ile Val Ala Glu Leu Phe Ser Gln Gly Pro Arg Pro Ala Ala Met Ala Val Ala Gly Phe Ser Asn Trp Thr Ser Asn Phe Ile Ile Gly Met Gly Phe Gln Tyr Val Ala Glu Ala Met Gly Pro Tyr Val Phe Leu Leu Phe Ala Val Leu Leu Leu Gly Phe Phe Ile Phe Thr Phe Leu Arg Val Pro Glu Thr Arg Gly Arg Thr Phe Asp Gln Ile Ser Ala Ala Phe His Arg Thr Pro Ser Leu Leu Glu Gln Glu Val Lys Pro 3( Ser Thr Glu Leu Glu Tyr Leu Gly Pro Asp Glu Asn Asp <210> 3 <211> 7809 <212> DNA

<213> Saccharomyces cerevisiae <400> 3 cgtaggaaca aattcgggcc cctgcgtgtt cttctgaggt tcatctttta catttgcttc 60 tgctggataa ttttcagagg caacaaggaa aaattagatg gcaaaaagtc gtctttcaag 120 gaaaaatccc caccatcttt cgagatcccc tgtaacttat tggcaactga aagaatgaaa 180 aggaggaaaa tacaaaatat actagaactg aaaaaaaaaa agtataaata gagacgatat 240 atgccaatac ttcacaatgt tcgaatctat tcttcatttg cagctattgt aaaataataa 300 aacatcaaga acaaacaagc tcaacttgtc ttttctaaga acaaagaata aacacaaaaa 360 caaaaagttt ttttaatttt aatcaaaaaa tgccgtcggg cttccaacag ataggctccg 420 aagatgggga accccctcag cagcgagtga ctgggaccct ggtccttgct gtgttctctg 480 cggtgcttgg ctccctgcag tttgggtaca acattggggt catcaatgcc cctcaggagg 540 tgattgaaca gagctacaat gagacgtggc tggggaggca ggggcctgag ggacccagct 600 ccatccctcc aggcaccctc accaccctct gggccctctc catggccatc ttttccgtgg 660 gcggcatgat ttcctccttc ctcattggta tcatctctca gtggcttgga aggaaaaggg 720 ccatgctggt caacaatgtc ctggcggtgc tggggggcag cctcatgggc ctggccaacg 780 ctgctgcctc ctatgaaatg ctcatccttg gacgattcct cattggcgcc tactcagggc 840 tgacatcagg gctggtgccc atgtacgtgg gggagattgc tcccactcac ctgcggggcg 900 ccctggggac gctcaaccaa ctggccattg ttatcggcat tctgatcgcc caggtgctgg 960 gcttggagtc cctcctgggc actgccagcc tgtggccact gctcctgggc ctcacagtgc 1020 =37 tacctgccct cctgcagctg gtcctgctgc ccttctgtcc cgagagcccc cgctacctct 1080 acatcatcca gaatctcgag gggcctgcca gaaagagtct gaagcgcctg acaggctggg 1140 ccgatgtttc tggagtgctg gctgagctga aggatgagaa gcggaagctg gagcgtgagc 1200 ggccactgtc cctgctccag ctcctgggca gcggtaccca ccggcagccc ctgatcattg 1260 cggtcgtgct gcagctgagc cagcagctct ctggcatcaa tgctgttttc tattattcga 1320 ccagcatctt cgagacagca ggggtaggcc agcctgccta tgccaccata ggagctggtg 1380 tggtcaacac agtcttcacc ttggtctcgg tgttgttggt ggagcgggcg gggcgccgga 1440 cgctccatct cctgggcctg gcgggcatgt gtggctgtgc catcctgatg actgtggctc 1500 tgctcctgct ggagcgagtt ccagccatga gctacgtctc cattgtggcc atctttggct 1560 tcgtggcatt ttttgagatt ggccctggcc ccattccttg gttcatcgtg gccgagctct 1620 tcagccaggg acgccgcccg gcagccatgg ctgtggctgg tttctccaac tggacgagca 1680 acttcatcat tggcatgggt ttccagtatg ttgcggaggc tatggggccc tacgtcttcc 1740 ttctatttgc ggtcctcctg ctgggcttct tcatcttcac cttcttaaga gtacctgaaa 1800 ctcgaggccg gacgtttgac cagatctcag ctgccttcca ccggacaccc tctcttttag 1860 agcaggaggt gaaacccagc acagaacttg agtatttagg gccagatgag aacgactgac 1920 tcgagtcatg taattagtta tgtcacgctt acattcacgc cctcccccca catccgctct 1980 aaccgaaaag gaaggagtta gaaaacctga agtctaggtc cctatttatt tttttatagt 2040 tatgttagta ttaagaacgt tatttatatt tcaaattttt cttttttttc tgtacagaog 2100 cgtgtacgca tgtaacatta tactgaaaac cttgcttgag aaggttttgg gacgctcgaa 2160 ggctttaatt tgcggccggt acccaattcg ccctatagtg agtcgtatta cgcgcgctca 2220 ctggccgtcg ttttacaacg tcgtgactgg gaaaaccctg gcgttaccca acttaatcgc 2280 cttgcagcac atcccccttt cgccagctgg cgtaatagcg aagaggcccg caccgatcgc 2340 ccttcccaac agttgcgcag cctgaatggc gaatggcgcg acgcgccctg tagcggcgca 2400 ttaagcgcgg cgggtgtggt ggttacgcgc agcgtgaccg ctacacttgc cagcgcccta 2460 gcgcccgctc ctttcgcttt cttcccttcc tttctcgcaa cgttcgccgg ctttccccgt 2520 caagctctaa atcgggggct ccctttaggg ttccgattta gtgctttacg gcacctcgac 2580 cccaaaaaac ttgattaggg tgatggttca cgtagtgggc catcgccctg atagacggtt 2640 tttcgccctt tgacgttgga gtccacgttc tttaatagtg gactcttgtt ccaaactgga 2700 acaacactca acectatctc ggtctattct tttgatttat aagggatttt gccgatttcg 2760 gcctattggt taaaaaatga gctgatttaa caaaaattta acgcgaattt taacaaaata 2820 ttaacgttta caatttcctg atgcggtatt ttctccttac gcatctgtgc ggtatttcac 2880 accgcatagg gtaataactg atataattaa attgaagctc taatttgtga gtttagtata 2940 catgcattta cttataatac agttttttag ttttgctggc cgcatcttct caaatatgct 3000 tcccagcctg cttttctgta acgttcaccc tctaccttag catcccttcc ctttgcaaat 3060 agtcctcttc caacaataat aatgtcagat cctgtagaga ccacatcatc cacggttcta 3120 tactgttgac ccaatgcgtc tcccttgtca tcaaaaccca caccgggtgt cataatcaac 3180 caatcgtaac cttcatctct tccacccatg tctctttgag caataaagcc gataacaaaa 3240 tctttgtcgc tcttcgcaat gtcaacagta cccttagtat attctccagt agatagggag 3300 cccttgcatg acaattctgc taacatcaaa aggcctctag gttcctttgt tacttcttct 3360 gccgcctgct tcaaaccgct aacaatacct gggcccacca caccgtgtgc attcgtaatg 3420 tctgcccatt ctgctattct gtatacaccc gcagagtact gcaatttgac tgtattacca 3480 atgtcagcaa attttctgtc ttcgaagagt aaaaaattgt acttggcgga taatgccttt 3540 agcggcttaa ctgtgccctc catggaaaaa tcagtcaaga tatccacatg tgtttttagt 3600 aaacaaattt tgggacctaa tgcttcaact aactccagta attccttggt ggtacgaaca 3660 tccaatgaag cacacaagtt tgtttgcttt tcgtgoatga tattaaatag cttggcagca 3720 acaggactag gatgagtagc agcacgttcc ttatatgtag ctttcgacat gatttatctt 3780 cgtttcctgc aggtttttgt tctgtgcagt tgggttaaga atactgggca atttcatgtt 3840 tcttcaacac tacatatgcg tatatatacc aatctaagtc tgtgctcctt ccttcgttct 3900 tccttctgtt cggagattac cgaatcaaaa aaatttcaaa gaaaccgaaa tcaaaaaaaa 3960 gaatacaaaa aaaatgatga attgaattga aaagctgtgg tatggtgcac tctcagtaca 4020 atctgctctg atgccgcata gttaagccag ccccgacacc cgccaacacc cgctgacgcg 4080 ccctgacggg cttgtctgct cccggcatcc gcttacagac aagctgtgac cgtctccggg 4140 agctgcatgt gtcagaggtt ttcaccgtca tcaccgaaac gcgcgagacg aaagggcctc 4200 gtgatacgcc tatttttata ggttaatgtc atgataataa tggtttctta gtatgatcca 4260 atatcaaagg aaatgatagc attgaaggat gagactaatc caattgagga gtggcagcat 4320 atagaacagc taaagggtag tgctgaagga agcatacgat accccgcatg gaatgggata 4380 atatcacagg aggtactaga ctacctttca tcctacataa atagacgcat ataagtacgc 4440 atttaagcat aaacacgcac tatgccgttc ttctcatgta tatatatata caggcaacac 4500 gcagatatag gtgcgacgtg aacagtgagc tgtatgtgcg cagctcgcgt tgcattttcg 4560 gaagcgctcg ttttcggaaa cgctttgaag ttcctattcc gaagttccta ttctctagaa 4620 '3 R

agtataggaa cttcagagcg cttttgaaaa ccaaaagcgc tctgaagacg cactttcaaa 4680 aaaccaaaaa cgcaccggac tgtaaggagc tactaaaata ttgcgaatac cgcttccaca 4740 aacattgctc aaaagtatct ctttgctata tatctctgtg ctatatccct atataaccta 4800 cccatccacc tttcgctcat tgaacttgca tctaaactcg acctctacat tttttatgtt 4860 tatctctagt attactcttt agacaaaaaa attgtagtaa gaactattca tagagtgaat 4920 cgaaaacaat acgaaaatgt aaacatttcc tatacgtagt atatagagac aaaatagaag 4980 aaaccgttca taattttctg accaatgaag aatcatcaac gctatcactt tctgttcaca 5040 aagtatgcgc aatccacatc ggtatagaat ataatcgggg atgcctttat cttgaaaaaa 5100 tgcacccgca gcttcgctag taatcagtaa acgcgggaag tggagtcagg ctttttttat 5160 ggaagagaaa atagacacca aagtagcctt cttctaacct taacggacct acagtgcaaa 5220 aagttatcaa gagactgcat tatagagcgc acaaaggaga aaaaaagtaa tctaagatgc 5280 tttgttagaa aaatagcgct ctcgggatgc atttttgtag aacaaaaaag aagtatagat 5340 tctttgttgg taaaatagcg ctctcgcgtt gcatttctgt tctgtaaaaa tgcagctcag 5400 attctttgtt tgaaaaatta gcgctctcgc gttgcatttt tgttttacaa aaatgaagca 5460 cagattcttc gttggtaaaa tagcgctttc gcgttgcatt tctgttctgt aaaaatgcag 5520 ctcagattct ttgtttgaaa aattagcgct ctcgcgttgc atttttgttc tacaaaatga 5580 agcacagatg cttcgttcag gtggcacttt tcggggaaat gtgcgcggaa cccctatttg 5640 tttatttttc taaatacatt caaatatgta tccgctcatg agacaataac cctgataaat 5700 gcttcaataa tattgaaaaa ggaagagtat gagtattcaa catttccgtg tcgcccttat 5760 tccctttttt gcggcatttt gccttcctgt ttttgctcac ccagaaacgc tggtgaaagt 5820 aaaagatgct gaagatcagt tgggtgcacg agtgggttac atcgaactgg atctcaacag 5880 cggtaagatc cttgagagtt ttcgccccga agaacgtttt ccaatgatga gcacttttaa 5940 agttctgcta tgtggcgcgg tattatcccg tattgacgcc gggcaagagc aactcggtcg 6000 ccgcatacac tattctcaga atgacttggt tgagtactca ccagtcacag aaaagcatct 6060 tacggatggc atgacagtaa gagaattatg cagtgctgcc ataaccatga gtgataacac 6120 tgcggccaac ttacttctga caacgatcgg aggaccgaag gagctaaccg cttttttgca 6180 caacatgggg gatcatgtaa ctcgccttga tcgttgggaa ccggagctga atgaagccat 6240 accaaacgac gagcgtgaca ccacgatgcc tgtagcaatg gcaacaacgt tgcgcaaact 6300 attaactggc gaactactta ctctagcttc ccggcaacaa ttaatagact ggatggaggc 6360 ggataaagtt gcaggaccac ttctgcgctc ggcccttccg gctggctggt ttattgctga 6420 Yo taaatctgga gccggtgagc gtgggtctcg cggtatcatt gcagcactgg ggccagatgg 6480 taagccctcc cgtatcgtag ttatctacac gacggggagt caggcaacta tggatgaacg 6540 aaatagacag atcgctgaga taggtgcctc actgattaag cattggtaac tgtcagacca 6600 agtttactca tatatacttt agattgattt aaaacttcat ttttaattta aaaggatcta 6660 ggtgaagatc ctttttgata atctcatgac caaaatccct taacgtgagt tttcgttcca 6720 ctgagcgtca gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcg 6780 cgtaatctgc tgcttgcaaa caaaaaaacc accgctacca gcggtggttt gtttgccgga 6840 tcaagagcta ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa 6900 tactgtcctt ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc 6960 tacatacctc gctctgctaa tcctgttacc agtggctgct gccagtggcg ataagtcgtg 7020 tcttaccggg ttggactcaa gacgatagtt accggataag gcgcagcggt cgggctgaac 7080 ggggggttcg tgcacacagc ccagcttgga gcgaacgacc tacaccgaac tgagatacct 7140 acagcgtgag ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc 7200 ggtaagcggc agggtcggaa caggagagcg cacgagggag cttccagggg gaaacgcctg 7260 gtatctttat agtcctgtcg ggtttcgcca cctctgactt gagcgtcgat ttttgtgatg 7320 ctcgtcaggg gggcggagcc tatggaaaaa cgccagcaac gcggcctttt tacggttcct 7380 ggccttttgc tggccttttg ctcacatgtt ctttcctgcg ttatcccctg attctgtgga 7440 taaccgtatt accgcctttg agtgagctga taccgctcgc cgcagccgaa cgaccgagcg 7500 cagcgagtca gtgagcgagg aagcggaaga gcgcccaata cgcaaaccgc ctctccccgc 7560 gcgttggccg attcattaat gcagctggca cgacaggttt cccgactgga aagcgggcag 7620 tgagcgcaac gcaattaatg tgagttacct cactcattag gcaccccagg ctttacactt 7680 tatgcttccg gctcctatgt tgtgtggaat tgtgagcgga taacaatttc acacaggaaa 7740 cagctatgac catgattacg ccaagcgcgc aattaaccct cactaaaggg aacaaaagct 7800 ggagctttt 7809

Claims (21)

Claims:

1. A purified and isolated polynucleotide, which comprises a DNA sequence coding for a protein GLUT4V85M, whereby the polynucleotide is selected from:
a) a nucleotide sequence according to SEQ ID NO:1 or b) a nucleotide sequence which hybridizes to the sequence of SEQ ID
NO:1 under stringent conditions and which codes for the protein GLUT4V85M, whereby stringent hybridization conditions comprise hybridization in an aqueous solution containing 2xSSC at 68oC for at least 2 hours, and washing in 2xSSC/0.1% SDS at room temperature for 5 minutes, in 1xSSC/0.1% SDS at 68oC for 1 hour and in 0.2xSSC/0.1 % SDS at 68oC for 1 hour.

2. The polynucleotide as claimed in claim 1, wherein the protein GLUT4V85M has an amino acid sequence according to SEQ ID NO:2.

3. The polynucleotide as claimed in claim 1 or 2, in which the DNA sequence coding for the protein GLUT4V85M is operationally linked to a promotor.

4. The polynucleotide as claimed in any one of claims 1 to 3, which can be replicated in a yeast cell.

5. The polynucleotide as claimed in claim 4, which can be used to express a protein in a yeast cell.

6. A Saccharomyces cerevisiae yeast cell, wherein all glucose transporters are no longer functional and which contains no functional Erg4 protein, and which comprises a polynucleotide as claimed in any one of claims 1 to 5.

7. The yeast cell as claimed in claim 6, comprising a protein GLUT4V85M.

8. The yeast cell of claim 6 or 7, which contains no functional Fgy1 protein.

9. The yeast cell as claimed in any one of claims 6 to 8, wherein the ERG4 gene is completely or partially deleted.

10. The yeast cell as claimed in claim 6 or 7, deposited as Saccharomyces cerevisiae DSM 15185.

11. The yeast cell as claimed in claim 8, deposited as Saccharomyces cerevisiae DSM 15186.

12. A process of preparing a yeast cell as claimed in any one of claims 6, 7 or 10, which comprises the steps:
a) providing a yeast cell wherein all glucose transporters are no longer functional and which contains no functional Erg4 protein, b) providing a polynucleotide as claimed in any one of claims 1 to 5, c) transforming the yeast cell as claimed in a) with the polynucleotide as claimed in b), d) selecting a transformed yeast cell, and e) where appropriate, expressing a protein GLUT4V85M.

13. A process of preparing a yeast cell as claimed in claim 8 or 11, which comprises the steps:
a) providing a yeast cell, wherein all glucose transporters are no longer functional and which contains no functional Fgy1 protein and no functional Erg4 protein, b) providing a polynucleotide as claimed in any one of claims 1 to 5, c) transforming the yeast cell as claimed in a) with the polynucleotide as claimed in b), d) selecting a transformed yeast cell, and e) where appropriate, expressing a protein GLUT4V85M.

14. A yeast cell whose glucose transporters in their entirety are no longer functional, comprising a polynucleotide as claimed in any one of claims 1 to 5.

15. The yeast cell as claimed in claim 14, comprising a protein GLUT4V85M.

16. The yeast cell as claimed in claim 14 or 15, deposited as Saccharomyces cerevisiae DSM 15188.

17. A process of preparing a yeast cell as claimed in any one of claims 14 to 16, which comprises the steps:
a) producing a yeast cell whose glucose transporters in their entirety are no longer functional, b) providing a polynucleotide as claimed in any one of claims 1 to 5, c) transforming the yeast cell as claimed in a) with the polynucleotide as claimed in b).
d) selecting a transformed yeast cell, and e) where appropriate, expressing a protein GLUT4V84M.

18. A protein having the functional activity of a glucose transporter, which is encoded by a polynucleotide sequence as claimed in claim 1 or 2.

19. The protein as claimed in claim 18, comprising an amino acid sequence according to SEQ ID NO:2.

20. A method for identifying a compound which stimulates the activity of a GLUT4 protein, which comprises the steps:
a) providing a yeast cell as claimed in any one of claims 6, 7 or 10, b) providing a chemical compound, c) contacting the yeast of a) with the chemical compound of b), d) determining glucose uptake by the yeast of c), and e) relating the detected value of the glucose uptake of d) to the detected value of glucose uptake in a yeast cell as claimed in a) which is not contacted with a chemical compound as claimed in b), with a compound which causes an increase in the amount of glucose taken up in the yeast as claimed in d) stimulating the activity of said GLUT4 protein.

21. A method for identifying a compound which inhibits the protein encoded by the ERG4 gene, which method comprises the steps:
a) providing a yeast cell as claimed in any one of claims 14 to 17, b) providing a chemical compound c) contacting the yeast of a) with the chemical compound of b), d) determining glucose uptake by the yeast of c), and e) relating the detected value of the glucose uptake of d) to the detected value of glucose uptake in a yeast cell as claimed in a) which is not contacted with a chemical compound as claimed in b), with a compound which causes an increase in the amount of glucose taken up in the yeast as claimed in d) inhibiting the activity of a protein Erg4.